Numaferm, a Germany-based peptide-focused spinout from Heinrich Heine University Düsseldorf, closed a seed round that featured the investment subsidiary of speciality chemicals producer Evonik Industries, Evonik Venture Capital, on Monday.

Evonik was joined by German public-private partnership High-Tech Gründerfonds (HTGF) and assorted angel investors, including Detlev Riesner and Jürgen Schumacher. While no specific figure was provided for the round, it is in the single digit million-euro range (€1m = $1.2m) range.

Numaferm previously raised a first tranche of undisclosed size…